Table 5.
The predictive value of PCDH17 methylation for the five-year overall survival in ccRCC.
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Sex (Male vs. Female) | 1.133 | 0.765–2.068 | 0.3426 | |||
| Age (≥60 vs. <60) | 1.263 | 0.831–2.179 | 0.1683 | |||
| Pathological stage (T3 vs. T1/T2) | 2.476 | 1.128–7.336 | 0.0268 | 1.463 | 0.874–3.421 | 0.0769 |
| Fuhrman grade (III/IV vs. I/II) | 3.042 | 1.363–8.546 | 0.0043 | 2.127 | 1.093–5.862 | 0.0347 |
| Lymph node metastasis (N1 vs. N0) | 3.925 | 1.833–10.796 | <0.0001 | 2.563 | 1.248–7.552 | 0.0163 |
| PCDH17 methylation (M vs. U) | 3.673 | 1.615–7.435 | 0.0003 | 2.876 | 1.347–8.065 | 0.0097 |
HR – hazard ratio; M – methylated; U – unmethylated.